ElectroCore, Inc. Announces Resignation of Frank Amato as Chief Executive Officer and a Member of the Board
June 10, 2019 at 06:36 pm IST
Share
On June 10, 2019, electroCore, Inc. announced that, in light of the results of the annual meeting of shareholders of the Company, Frank Amato, Chief Executive Officer of the Company, offered his resignation to the board of directors (the Board). The Company and Mr. Amato entered into a Separation Agreement (the Agreement), pursuant to which he will remain as Chief Executive Officer and a member of the Board until the earlier of such time as a new chief executive officer is recruited and September 30, 2019, subject to extension by mutual agreement of the parties.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company. It provides non-invasive vagus nerve stimulation (nVNS) technology platform. The Companyâs product categories include Handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headache, and Handheld, personal use consumer products utilizing nVNS technology to promote general wellness and human performance. Its products include gammaCore, Truvaga and TAC-STIM. Its gammaCore Sapphire, is a prescription medical device that is used for a variety of primary headache conditions. Its Truvaga is a personal use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com. The Companyâs TAC-STIM product is not a medical device and is not intended to diagnose, cure, mitigate, prevent, or treat a disease or condition.